Alliance Pharma plc

APH

GB0031030819

Pharmaceuticals

Delayed London S.E. Other stock markets 08:34:04 15/01/2025 GMT			5-day change	1st Jan Change
61.40 ^GBX	+0.49%		+39.12%	+33.80%

01-10	FTSE 100 down, sterling has yet to recover	AN
01-10	Stocks weak, sterling steady, as jobs data looms	AN

Alliance Pharma plc Provides Revenue Guidance for the Full Year 2024

September 30, 2024 at 10:00 am

Alliance Pharma plc provided revenue guidance for the full year 2024. for the year, the company expects mid-single-digit revenue growth.

Latest news about Alliance Pharma plc

FTSE 100 down, sterling has yet to recover	01-10	AN
Stocks weak, sterling steady, as jobs data looms	01-10	AN
AIM WINNERS & LOSERS: Anpario expects 2024 earnings beat	01-10	AN
Alliance Pharma agrees GBP350 million takeover by largest shareholder	01-10	AN
Tepid trade before afternoon's US jobs report	01-10	AN
Alliance Pharma Accepts GBP350 Million Takeover Offer from Top Shareholder	01-10	MT
Sainsbury's hails "biggest ever Christmas"	01-10	AN
Asset management firm DBAY to buy UK's Alliance Pharma in $430 million deal	01-10	RE
An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. and an undisclosed buyer reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc from Andrew Franklin and Richard Jones for approximately £250 million.	01-09	CI
EARNINGS: Alliance Pharma swings to profit; DG Innovate loss widens	30/09/24	AN
Alliance Pharma plc Provides Revenue Guidance for the Full Year 2024	30/09/24	CI
Alliance Pharma plc, H1 2024 Earnings Call, Sep 30, 2024	30/09/24
Earnings Flash (APH.L) ALLIANCE PHARMA Reports H1 Revenue GBP83.9M	30/09/24	MT
Earnings Flash (APH.L) ALLIANCE PHARMA Posts H1 EPS GBX0.86	30/09/24	MT
Alliance Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2024	30/09/24	CI
Alliance Pharma plc Announces Termination of Jeyan Heper as Director	01/09/24	CI
EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx	12/08/24	AN
HSS Hire Group's Interim CFO Takes Office	12/08/24	MT
Alliance Pharma trading in line, revenue edges higher	29/07/24	AN
Alliance Pharma nixes chief operating officer role	23/07/24	AN
Alliance Pharma COO to Depart	23/07/24	MT
Alliance Pharma plc Announces Jeyan Heper to Leave the Business as Chief Operating Officer, Effective 31 August 2024	23/07/24	CI
Alliance Pharma plc Announces Termination of Mr. Peter Jonathan Butterfield as Director	01/07/24	CI
Alliance Pharma plc, 2023 Earnings Call, Jun 19, 2024	19/06/24
Alliance Pharma plc Provides Preliminary Results for the Year Ended 31 December 2023	19/06/24	CI

Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.

Employees

290

Sector

Pharmaceuticals

Calendar

24/03/2025 - Q4 2024 Earnings Release (Projected)

More about the company